<DOC>
	<DOCNO>NCT01416974</DOCNO>
	<brief_summary>The purpose Phase I study test safety effect specially prepared cell collect patient call `` modified T cell . '' We want find safe dose modify T cell patient disease remain initial chemotherapy . We also want find effect T cell leukemia .</brief_summary>
	<brief_title>Consolidation Therapy With Autologous T Cells Genetically Targeted B Cell Specific Antigen CD19 Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin , Cyclophosphamide Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>CLL patient evidence residual disease , achieve PR , nPR CR detectable MRD follow upfront therapy consist pentostatin , cyclophosphamide rituximab . The presence MRD assess flow cytometry polymerasechain reaction MSKCC Diagnostic Molecular Pathology Laboratory . Age ≥ 18 year age . Creatinine ≤2.0 mg/100 ml , bilirubin ≤2.0 mg/100 ml , AST ALT ≤3.0x normal , PT PTT ≤2x normal outside set stable chronic anticoagulation therapy , absolute neutrophil count ≥500/mm3 , platelets ≥50,000/mm3 , hemoglobin ≥8.0g/dl transfusion support . Adequate pulmonary function assess ≥92 % oxygen saturation room air pulse oximetry . Karnofsky performance status &lt; 70 . Pregnant lactating woman . Women men childbearing age use effective contraception study continue 1 year treatment finish . Impaired cardiac function ( LVEF &lt; 40 % ) assess ECHO MUGA scan . Patients previously treat allogeneic bone marrow stem cell transplantation ineligible . Patients immediate candidate allogeneic bone marrow stem cell transplantation . Patients refuse option remain eligible need document patient medical record . CLL patient transform disease ( Richter 's transformation ) ineligible enrollment study . Patients follow cardiac condition exclude : New York Heart Association ( NYHA ) stage III IV congestive heart failure Myocardial infarction ≤6 month prior enrollment History clinically significant ventricular arrhythmia unexplained syncope , believe vasovagal nature due dehydration History severe nonischemic cardiomyopathy EF ≤20 % Patients HIV active hepatitis B hepatitis C infection ineligible . Patients concurrent active malignancy define malignancy require therapy expectant observation , exception squamous basal cell carcinoma skin . STEP 2 REGISTRATION ( Treatment ) : The follow additional criterion must meet order patient eligible receive modify T cell infusion . These lab obtain within 2 week T cell infusion . Creatinine ≤2.0 mg/100 ml , bilirubin ≤2.0 mg/100 ml , AST ALT ≤3.0x normal , PT PTT ≤2x normal outside set stable chronic anticoagulation therapy , absolute neutrophil count ≥500/mm3 , platelets ≥50,000/mm3 , hemoglobin ≥8.0g/dl transfusion support .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>19-28Z RETROVIRUS</keyword>
	<keyword>CYCLOPHOSPHAMIDE ( CYTOXAN )</keyword>
	<keyword>autologous T cell</keyword>
	<keyword>Leukapheresis</keyword>
	<keyword>11-048</keyword>
</DOC>